thioridazine has been researched along with Weight Gain in 4 studies
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thioridazine (Mellaril(R)) was given to 104 psychiatric patients with a variety of illnesses, chiefly schizophrenic reactions." | 1.24 | Thioridazine (mellaril) in psychiatric patients. ( HOLLISTER, LE; MACDONALD, BF, 1959) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kroeze, WK | 1 |
| Hufeisen, SJ | 1 |
| Popadak, BA | 1 |
| Renock, SM | 1 |
| Steinberg, S | 1 |
| Ernsberger, P | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 1 |
| Roth, BL | 1 |
| Gupta, S | 1 |
| CASTELNUOVO-TEDESCO, P | 1 |
| TANGUAY, PE | 1 |
| PROUT, BM | 1 |
| BURGESS, EC | 1 |
| HOLLISTER, LE | 1 |
| MACDONALD, BF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
1 review available for thioridazine and Weight Gain
| Article | Year |
|---|---|
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
3 other studies available for thioridazine and Weight Gain
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Hum | 2003 |
Galactorrhea, headache and weight-gain during treatment with thioridazine.
Topics: Amenorrhea; Body Weight; Female; Galactorrhea; Headache; Humans; Lactation Disorders; Pregnancy; Thi | 1963 |
Thioridazine (mellaril) in psychiatric patients.
Topics: Antipsychotic Agents; Double-Blind Method; Electroconvulsive Therapy; Humans; Mental Disorders; Psyc | 1959 |